Isodiol International Inc. Signs Definitive Agreement to Acquire 100% of Be Trū Organics™

VANCOUVER, British Columbia, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global bioactive phytoceutical innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce that it has finalized the definitive agreement to acquire 100% of Be Trū Organics™, a cause driven organization specializing in holistic products for everyday health and balance in the human body with the goal to promote well-being within the mind, body, & soul.

This news is in connection with Isodiol’s previous announcement confirming the Company had entered into a binding agreement with Be Trū Organics. The press release can be viewed here.

“The acquisition with Be Trū Organics is yet another major milestone for Isodiol and we are very pleased to have been able to finalize this partnership so quickly,” said Marcos Agramont, CEO of Isodiol. “Not only does this partnership add diversity to the Isodiol’s already strong portfolio of products, but gives the Company access to the mainstream distribution channels that Be Trū Organics has been able to penetrate.”

There have been no changes to the terms of this agreement. Isodiol will issue Be Trū Organics $2,000,000 USD in stock, subject to a 36-month escrow.

For more information on Isodiol, please visit www.isodiol.com

For more information on Be Trū Organics™, please visit www.betruorganics.com

About Isodiol International Inc.

Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.

Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.

Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter: @isodiol

Marcos Agramont, CEO & Director


Carrie Booze
North 6th Agency
212-334-9753 ext.142

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future of the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.